Experimental Hematology
Volume 38, Issue 2 , Pages 124-131.e4 , February 2010

A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients

  • Klaudia Kuranda

      Affiliations

    • INSERM, Unité 837, Institut de Recherche sur le Cancer de Lille, Lille, France
    • Université de Lille 2 Institut Fédératif de Recherche 114, Lille, France
    • Drs. Kuranda and Berthon contributed equally to this work.
    • ,
  • Céline Berthon

      Affiliations

    • INSERM, Unité 837, Institut de Recherche sur le Cancer de Lille, Lille, France
    • Université de Lille 2 Institut Fédératif de Recherche 114, Lille, France
    • Service des Maladies du Sang, Centre Hospitalier et Universitaire de Lille, Lille, France
    • Drs. Kuranda and Berthon contributed equally to this work.
    • ,
  • Caroline Dupont

      Affiliations

    • INSERM, Unité 837, Institut de Recherche sur le Cancer de Lille, Lille, France
    • Université de Lille 2 Institut Fédératif de Recherche 114, Lille, France
    • ,
  • Dariusz Wolowiec

      Affiliations

    • Department of Hematology, Wroclaw Medical University, Wroclaw, Poland
    • ,
  • Xavier Leleu

      Affiliations

    • INSERM, Unité 837, Institut de Recherche sur le Cancer de Lille, Lille, France
    • Université de Lille 2 Institut Fédératif de Recherche 114, Lille, France
    • Service des Maladies du Sang, Centre Hospitalier et Universitaire de Lille, Lille, France
    • ,
  • Renata Polakowska

      Affiliations

    • INSERM, Unité 837, Institut de Recherche sur le Cancer de Lille, Lille, France
    • Université de Lille 2 Institut Fédératif de Recherche 114, Lille, France
    • ,
  • Nathalie Jouy

      Affiliations

    • Université de Lille 2 Institut Fédératif de Recherche 114, Lille, France
    • ,
  • Bruno Quesnel

      Affiliations

    • INSERM, Unité 837, Institut de Recherche sur le Cancer de Lille, Lille, France
    • Université de Lille 2 Institut Fédératif de Recherche 114, Lille, France
    • Service des Maladies du Sang, Centre Hospitalier et Universitaire de Lille, Lille, France
    • Corresponding Author InformationOffprint requests to: Bruno Quesnel, M.D., Ph.D., Service des Maladies du Sang, Centre Hospitalier et Universitaire de Lille, Rue Polonovski, 59037, Lille, France

Received 22 April 2009 ,Revised 13 November 2009 ,Accepted 23 November 2009.

References 

  1. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008;26:2895–2900
  2. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68:190–197
  3. Bataille R, Robillard N, Pellat-Deceunynck C, Amiot M. A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. Immunol Rev. 2003;194:105–111
  4. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704
  5. Vescio RA, Hong CH, Cao J, et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood. 1994;84:3283–3290
  6. Johnson RJ, Owen RG, Smith GM, et al. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplant. 1996;17:723–727
  7. Schiller G, Vescio R, Freytes C, et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood. 1995;86:390–397
  8. Owen RG, Haynes AP, Evans PA, et al. Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection. Clin Mol Pathol. 1996;49:M112–M117
  9. Willems P, Croockewit A, Raymakers R, et al. CD34 selections from myeloma peripheral blood cell autografts contain residual tumour cells due to impurity, not to CD34+ myeloma cells. Br J Haematol. 1996;93:613–622
  10. Schiller G, Vescio R, Freytes C, et al. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant. 1998;21:141–145
  11. Rasmussen T, Jensen L, Honore L, Andersen H, Johnsen HE. Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays. Br J Haematol. 1999;107:818–824
  12. Rasmussen T, Kastrup J, Knudsen LM, Johnsen HE. High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma. Br J Haematol. 1999;105:265–267
  13. Rasmussen T, Bjorkstrand B, Andersen H, Gaarsdal E, Johnsen HE. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study. Exp Hematol. 2002;30:82–88
  14. Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19:3771–3779
  15. Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood. 1999;93:1858–1868
  16. Mahe B, Milpied N, Hermouet S, et al. G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma. Br J Haematol. 1996;92:263–268
  17. Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110:296–304
  18. Knudsen LM, Rasmussen T, Nikolaisen K, Johnsen HE. Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma. Eur J Haematol. 2001;67:289–295
  19. Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood. 1997;89:1824–1833
  20. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332–2336
  21. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res. 2005;11:7599–7606
  22. Dalton W, Anderson KC. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin Cancer Res. 2006;12:6603–6610
  23. Dao MA, Arevalo J, Nolta JA. Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood. 2003;101:112–118
  24. Dooley DC, Oppenlander BK, Xiao M. Analysis of primitive CD34- and CD34+ hematopoietic cells from adults: gain and loss of CD34 antigen by undifferentiated cells are closely linked to proliferative status in culture. Stem Cells. 2004;22:556–569
  25. Zanjani ED, Almeida-Porada G, Livingston AG, Zeng H, Ogawa M. Reversible expression of CD34 by adult human bone marrow long-term engrafting hematopoietic stem cells. Exp Hematol. 2003;31:406–412

PII: S0301-472X(09)00452-4

doi: 10.1016/j.exphem.2009.11.008

Experimental Hematology
Volume 38, Issue 2 , Pages 124-131.e4 , February 2010

Article Tools

* Image Usage & Resolution